ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: TH-PO1102

Association Between Statin Use and Delirium in Critically Ill Patients with CKD: Retrospective Cohort Study from the MIMIC-IV Database

Session Information

Category: CKD (Non-Dialysis)

  • 2302 CKD (Non-Dialysis): Clinical, Outcomes, and Trials

Authors

  • Chen, Yuanhao, Department of Nephrology, The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, China
  • Chen, Liangmei, Department of Nephrology, The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, China
  • Liu, Fanna, Department of Nephrology, The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, China
Background

Delirium is a common and severe issue for ICU patients with CKD, linked to higher rates of illness and death. Statins, which have anti-inflammatory and endothelial-stabilizing effects, may offer neuroprotection. Yet, the link between statin use and delirium risk in CKD patients in the ICU is not well understood.

Methods

We conducted a retrospective cohort study using MIMIC-IV. Adult pts (≥18 y) with CKD admitted to ICU were included. Pts were grouped by in-hospital statin use. Primary outcome: ICU delirium incidence. 1:1 PSM was performed. Logistic regression assessed statin-delirium association. Cox models evaluated 30-/90-day mortality. Subgroup analyses included statin types and subgroups: age, sex, CHF, CAD, CeVD, COPD, DM, cancer, CKD stage, BZD/propofol use, CCI, SAPS, OASIS, SOFA

Results

A total of 3218 pts met inclusion criteria (statin: 1778, non-statin: 1440). The statin group was older (76.1 vs. 73.0 y, P<0.001) with more males (66.6% vs. 59.4%, P<0.001). After PSM, 1066 matched pairs were analyzed. Statin use was linked to lower delirium risk (25.8% vs. 34.3%, P<0.001). Adjusted logistic regression confirmed protection (OR: 0.60, 95% CI: 0.49–0.74, P<0.001). Subgroup analysis showed consistent delirium reduction across most subgroups, with an interaction between statin use and BZ use (P=0.009). Statins also reduced 30-/90-day mortality in univariate & multivariable Cox models. No significant difference between lipophilic/hydrophilic statins in delirium prevention.

Conclusion

Statin use is independently associated with reduced risk of delirium and improved short-term survival in ICU patients with CKD. These findings support further investigation of statins’ neuroprotective roles in this high-risk population.

KM survival curves of 90-day mortality within the ICU for patients in statin-exposure and Non-statin.

Funding

  • Government Support – Non-U.S.

Digital Object Identifier (DOI)